The results showed a significant increase in the number of TUNEL-positive points in senescent endothelial cells treated with FOXO4-DRI
Its four-amino acid sequence places it within the "short peptide bioregulator" class of compounds studied extensively in Eastern European gerontological research
T2DM is a leading risk factor for PAD, which limits physical functions
Many Gaia Herbs products are also Non-GMO Project Verified, and that list continues to grow
The new playbook involves: Complex generics : Injectables, respiratory/nasal sprays, ophthalmic, transdermal products with technical barriers that limit competition Controlled substances : A sub-theme gaining momentum at Strides through its Chestnut Ridge facility and DEA quota Biosimilars : The next major wave is pembrolizumab, bevacizumab, ranibizumab, trastuzumab 505(b)(2) specialty: Branded differentiated products filed through the 505(b)(2) pathway (Alembics PIVYA) Peptides: Semaglutide filings by Zydus and Lupin as the frontier opportunity 17) Lupin US - $1.3 Billion and Still Accelerating FY26 US : ~$1.3 Bn (+~40% YoY) | Q4 US: 33,987 Mn ($371 Mn, +55% YoY) Lupins US performance is the headline story of Q4 FY26
